⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL143892 | 0.80 | ALDH1A1 (0.38) | — | |
| SCHEMBL11324395 | 0.78 | — | — | |
| SCHEMBL1809 | 0.78 | — | — | |
| SCHEMBL8804677 | 0.76 | — | — | |
| SCHEMBL1728206 | 0.76 | — | — | |
| SCHEMBL26572 | 0.76 | — | — | |
| SCHEMBL1728266 | 0.76 | — | — | |
| SCHEMBL7277104 | 0.76 | — | — | |
| SCHEMBL55042 | 0.76 | — | — | |
| SCHEMBL1728210 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6262098-B1 | ISOXAZOLE ESTROGEN RECEPTOR AGONIST AND ANTAGONIST | CHIRON CORPORATION | 2001-07-17 | — | — | US | claimed |
| US-8921124-B2 | Pyrazole-based cyanine dye | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2014-12-30 | — | — | US | disclosed |
| WO-2012033298-A3 | METHOD FOR MANUFACTURING A NOX GAS SENSOR, AND NOX GAS SENSOR MANUFACTURED USING SAME | 일진머티리얼즈 주식회사 (KR) | 2012-05-10 | — | — | WO | disclosed |
| EP-2006289-B1 | PYRAZOLE-TYPE CYANINE DYE | WAKO PURE CHEM IND LTD (JP) | 2011-11-30 | — | — | EP | disclosed |
| US-20090069546-A1 | PYRAZOLE-BASED CYANINE DYE | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2009-03-12 | — | — | US | disclosed |
| EP-2006289-A1 | PYRAZOLE-TYPE CYANINE DYE | Wako Pure Chemical Industries, Ltd. (JP) | 2008-12-24 | — | — | EP | disclosed |
| US-7399884-B2 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2008-07-15 | — | — | US | disclosed |
| US-20070232654-A1 | Novel Compounds and Compositions as Cathepsin Inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2007-10-04 | — | — | US | disclosed |
| US-20070203138-A1 | Novel Compounds and Compositions as Cathepsin S Inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-08-30 | — | — | US | disclosed |
| US-7250514-B1 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-20040014796-A1 | Novel compounds and compositions as cathepsin S inhititors | AXYS PHARMACEUTICALS, INC. | 2004-01-22 | — | — | US | disclosed |
| US-20030199506-A1 | Novel compounds and compositions as cathepsin S inhibitors | AXYS PHARMACEUTICALS INC. | 2003-10-23 | — | — | US | disclosed |
| WO-2003042197-A1 | OLIGOPEPTIDES AND COMPOSITIONS CONTAINING THEM AS CATHEPSIN S INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2003-05-22 | — | — | WO | disclosed |
| WO-2003024924-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2003-03-27 | — | — | WO | disclosed |
| WO-2002098406-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-12-12 | — | — | WO | disclosed |
| WO-2002098850-A2 | CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-12-12 | — | — | WO | disclosed |
| US-6492362-B1 | Compounds and compositions as cathepsin S inhibitors | AXYS PHARMACEUTICALS, INC. | 2002-12-10 | — | — | US | disclosed |
| WO-2002051983-A2 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-07-04 | — | — | WO | disclosed |
| EP-1212302-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001019796-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2001-03-22 | — | — | WO | disclosed |